Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs (ACICOVID)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04373759 |
Recruitment Status :
Completed
First Posted : May 4, 2020
Last Update Posted : October 13, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19) pandemic. Among COVID-19 complications, in-hospital cardiac arrest (IHCA) was reported with a very poor outcome in a retrospective single-center study (0,7% of 30 days survival with good neurological outcome among IHCA patients with a resuscitation attempt), related to its natural course and management. The incidence of unexpected in-ICU cardiac arrest (ICUCA) due to COVID-19 is still unknown. Additionally, outcome of COVID-19 patients admitted in ICU for an out-of-hospital cardiac arrest (OHCA) is also undescribed.
The objective this study is :
- to report the incidence of ICUCA among patients hospitalized in French ICU for COVID-19.
- to report morbidity and mortality among COVID-19 patients admitted alive in ICU for an OHCA or an IHCA.
The secondary objective is to assess outcome and identify risk factors of ICUCA occurrence among patients admitted for COVID-19.
Condition or disease | Intervention/treatment |
---|---|
Sars-CoV2 Covid-19 | Other: Cardiopulmonary resuscitation Other: Modified Rankin score |
Retrospective and prospective multicentric observational registry in French intensive care units (ICU) including all consecutive adult patients admitted in ICU with a documented SARS-CoV-2 disease :
- For an out-of-hospital or an in-hospital cardiac arrest (OHCA and IHCA respectively)
- Or presenting an unexpected in-ICU cardiac arrest (ICUCA) Patients characteristics, cardiac arrest history and patients outcome will be recorded according to Utstein recommendations.
Patients presenting an expected cardiac arrest in ICU related to withdrawal of life sustaining therapies (WLST) will be excluded.
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 186 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 3 Months |
Official Title: | Cardiac Arrest Incidence and Outcome Among Patient With COVID-19 Pneumonia in French ICUs |
Actual Study Start Date : | May 2, 2020 |
Actual Primary Completion Date : | September 30, 2020 |
Actual Study Completion Date : | September 30, 2020 |

Group/Cohort | Intervention/treatment |
---|---|
Unexpected in-intensive care unit cardiac arrest patients
ICUCA Patients admitted in intensive care unit for a confirmed COVID-19 and presenting an unexpected in-intensive care unit cardiac arrest
|
Other: Cardiopulmonary resuscitation
Cardiopulmonary resuscitation Other: Modified Rankin score 0 - no symptoms at all
|
In-hospital cardiac arrest patients
IHCA Patients admitted in intensive care unit for an in-hospital cardiac arrest with a confirmed Covid-19
|
Other: Modified Rankin score
0 - no symptoms at all
|
Out-of-hospital cardiac arrest
OHCA Patients admitted in intensive care unit for an out-hospital cardiac arrest with a confirmed Covid-19
|
Other: Modified Rankin score
0 - no symptoms at all
|
- Incidence of unexpected cardiac arrest [ Time Frame: 7 months ]Percentage of unexpected in-intensive care unit cardiac arrest among COVID-19 patients admitted to intensive care unit
- Charlson score [ Time Frame: 7 months ]Diabetes, hypertension, smoking, dyslipidemia, coronary artery disease, chronic respiratory insufficiency, chronic heart failure, chronic renal insufficiency, chronic hepatic insufficiency, chronic neurological disease, cancer, malignant hemopathy. Charlson score's minimum and maximum values are 0 and 40 respectively, the lowest score corresponds to a better outcome.
- Organ failure score at ICU admission and/or before unexpected in-ICU cardiac arrest [ Time Frame: 7 months ]Respiratory failure, neurological impairment, circulatory failure, hepatic failure, haematological failure, renal failure. Sofa score's minimum and maximum values are 0 and 24, the lowest score corresponds to a better outcome
- Etiology retained to explain cardiac arrest occurrence [ Time Frame: 7 months ]Cardiac origin; Respiratory origin; Metabolic origin; unknown origin
- Modified Rankin score (mRS) at ICU discharge, at hospital discharge and at 3 months [ Time Frame: 3 months ]
0 - no symptoms at all
- - no significant disability despite symptoms; able to carry out all usual duties and activities
- - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
- - Moderate disability; requiring some help, but able to walk without assistance
- - Moderately severe disability; unable to walk and attend to bodily needs without assistance
- - Severe disability; bedridden, incontinent and requiring constant nursing care and attention
- - Dead

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients admitted in intensive care unit with a documented SARS-CoV-2 disease
- For an out-of-hospital or an in-hospital cardiac arrest
- Or an in-hospital cardiac arrest
- Or presenting an unexpected in-intensive care unit cardiac arrest
Exclusion Criteria:
- Age under 18 y.o
- Expected in-intensive care unit cardiac arrest related to withdrawal of life sustaining therapies.
- Withdrawal of patient or next-of-kin informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04373759

Study Director: | Jonathan Chelly, MD | Centre Hospitalier Intercommunal Toulon La Seyne sur Mer |
Other Publications:
Responsible Party: | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer |
ClinicalTrials.gov Identifier: | NCT04373759 |
Other Study ID Numbers: |
2020-CHITS-004 |
First Posted: | May 4, 2020 Key Record Dates |
Last Update Posted: | October 13, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
novel coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Out-of-hospital cardiac arrest |
In-hospital cardiac arrest unexpected cardiac arrest Intensive care unit |
COVID-19 Heart Arrest Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections |
Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Heart Diseases Cardiovascular Diseases |